Johnson & Johnson

3Q Revenues: $24.0 billion (+7%)

3Q Earnings: $5.2 billion (+91%)

YTD Revenues: $69.6 billion (+5%)

YTD Earnings: $21.7 billion (+104%)

Comments: Growth in the quarter was primarily driven by DARZALEX, CARVYKTI, ERLEADA and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience. 

DARZALEX sales were up 22% to $3.7 billion. CARVYKTI sales were up 84% to $524 million. ERLEADA sales were up 18% to $936 million. TREMFYA sales were $1.4 billion, up 41%. SIMPONI/SIMPONI ARIA sales were $687 million, up 33%. SPRAVATO sales were $459 million, up 62%

Growth was partially offset by sales declines for STELARA in Immunology, down 41% to $1.6 billion, and IMBRUVICA in Oncology, down 8% to $695 million. INVEGA SUSTENNA sales were down 11% to $929 million.

Earnings exclude intangible amortization expense and special items. Earnings reflect R&D program exits in infectious diseases and vaccines including the discontinuation of its RSV adult vaccine program, hepatitis and HIV development. The restructuring expense of $19 million in 3Q224 and $100 million 3Q24 YTD included the termination of partnered and non-partnered program costs, asset impairments and asset divestments.